Taiwan Medical And Biotech Industry Association

Introduction

This Association was established on February 3, 1953. Since all early members produced such consumables as medical cotton wool and gauze, etc., so this association was named as "Taiwan Absorbent Cotton Industry Association". Due to such factors as variation of the industrial structure year by year and redevelopment of administrative region, the name of this Association experienced with five amendments, and it was renamed as TAIWAN MEDICAL AND BIOTECH INDUSTRY ASSOCIATION in July 2003 till now. The chairman of this term (19th term) is acted by Mr. Francis Hong, the president of St. Francis Medical Equipment Co., LTD., and Mr. Tung Mao Su, the president of Chi Sheng Chemical Corp.. acts the convener of supervisors meeting. There are 27 directors of the board of directors, 9 supervisors of the board of supervisor, and a secretary-general in the secretariat. There are more than 360 members of this Association; they majorly produce such medical equipment as biochemical analyzer, oximeter, physiological minitor, home blood glucose meter, Extracorporeal Shock Wave Lithotriptor, blood pressure monitors, thermometers, Diagnostic Ultrasound Imager, transcutaneous electrical nerve stimulator, operating table (lamp), dental X-ray machine, treatment tables and chairs, laboratory equipment, hospital beds, wheelchair, Electric Scooters, Prosthesis, protectors, gauze dressings, bandages, surgical gowns and caps, infusion tubes, syringes, gloves, testing reagents, artificial hip joints, contact lenses and medicine, and collagen.

The Main Task

To actively and effective promote the business of this Association, six teams as Regulatory Affair, Activity, Cross-Strait affairs, Foreign Trade, and Industry-Academia-Research Committee, Public relations committee, Charity Committee, Member Recruitment Committee, and Activities Committee are established to assist the chairman.

Future Perspective

Over 60 years has been elapsed since this Association was established. Comparing to traditional industry, the industry was neglected no matter in the industry itself and the industry policy in the past; however, facing the opportunities and threats brought by the large changes in the environment, this Association will uphold the experience heritage in previous efforts and environmental trends in the development, to propose the White Paper on industrial policy-making to officials for reference, in the next gold ten years. The Association will focus on the promotion in the regulations, research of industry and academy, cross-strait affairs, as well as market development and so on, especially the manufacturers in the face of product innovation, R & D of high-end medical material. This Association hopes to play a positive and counseling role in promoting the interaction and symbiotic win-win relationship among industry, government, academic and research interaction and, and to establish a pragmatic mechanism for interdisciplinary exchange platform as communication, interaction, dialogue and research. It is expected to take this opportunity to lead the integration between industry and academia, industry and industry, alliances and international technical exchanges and cooperation, to create the best interface for the members of the Association to enhance its competitiveness.

TMBIATMBIATMBIA

 Message from Chairman 

Francis Hong
chairman

May 15, 2017

Chairman’s message
Taiwan Medical and Biotech Industry Association

I would like to take this opportunity to express my appreciation to all members and directors of the Taiwan Medical and Biotech Industry Association who elected me the 19th chairman of the association. I take this as a great challenge and responsibility for me.

The Taiwan Medical and Biotech Industry Association (TMBIA) has been established for more than 50 years. The current production value of Taiwan’s medical equipment is resulted from the constant and diligent efforts made by the industry. Have gained recognition and respect from the government and people from all walks of life, Taiwan’s medical industry has been made one of the 5+2 strategic industries for national development.

However, in the face of growing protectionism and the wave of anti-globalization, Taiwan’s medical industry, which is mainly based on small and medium enterprises, is unable to single-handedly make inroad into the overseas markets and suvive through their own brands, if without the injection of government resources.

To develop the biotech industry and medical equipment, the primary task for Taiwan is to stipulate the industrial policy for medical development jointly by the industry, the government, the academics, the research institutions, and the medical sector. Afterwards, the medical equipment makers could explore the markets abroad and involve in the international health and medical chains so as to gain business reputation. Additionally, the government should encourage the domestic medical facilities to utilize Taiwan-made medical devices. It is generally believed that under the government’s supports and the efforts made by the manufacturers of the medical devices, a handful of “TSMC” could be developed.

The Taiwan Medical and Biotech Industry Association backs the government in advancing the legislation of the “Medical Equipment Management Bill” and is pleased to see the relaxation of certain regulations concerned. We support the opening up of our doors to seeking foreign talents in order to escalate the level of our research and manufacturing. The association also appeals to the government to grant reasonable freedom of speech to the advertising given by our manufacturers of medical devices. We also urge that certification of international bilateral documents be conducted based on mutual benefits to reduce redundancy of factory examinations as well as clinical and non-clinical trials.

Unlike in the past when the medical and drug sector across the Taiwan Straits enjoyed more cooperation and negotiation, the Taiwan Food and Drug Administration (TFDA) the Ministry of Health and Welfare and the China Food and Drug Administration (CFDA) have stopped the regular negotiating mechanism. As a result of the lack of information exchanges on medical devices supervision and control, and the unawareness of our members towards mainland China’s changes of regulations, a great many resources have been wasted. The members of our association must make efforts to re-establish new relationships. With real ability, could they be able to market their products in the emerging markets of mainland China. The association should take initiative to establish a two-way mechanism to study “How to re-open negotiations” to catch hold of China’s business  opportunities, with the greatest haste in resuming and activating dialog on trade and regulations on medical industry across the Taiwan Straits.

Following the launch of the New Southbound Policy by the government, the responses of the TMBIA members are generally reflected as follows: To cope with the global economic structure and to explore more business opportunities, the government’s intention is good. Nevertheless, it does not totally meet the needs and demands of our member companies and the Southeast Asian nations. I therefore put forth a proposal: the Taiwan Medical and Biotech Industry Association integrates with member factories to call upon the government to provide effectives resources and funds to be used to help TMBIA set up overseas sales offices with the help of our representative offices or diplomatic organizations. We aim at proactively and aggressively seeking business opportunities for our members.

As most of our members are small and medium enterprises, the domestic market is not big enough to maintain the elementary business needs. In the face of competition by major foreign manufacturers, our members encounter even more hardship. I therefore propose that our members enter into an alliance with other industries, putting similar medical products’ rules and regulations, research and development, marketing and production into a suitable integration. Through integrated resources, concentration of resources and avoidance of wastage, our member factories would take a new way of business operation to cope with severe market challenges.

I have served for 24 years in the association, witnessing its growth and expansion. It is my pleasure to see the accomplishments if our members achieved through years of hard work and devotion. TMBIA is a precious public platform. Let’s build a bridge between our members, our government and the world, enabling the best made-in-Taiwan medical products to be sold worldwide and benefit all humanity.

The Taiwan Medical and Biotech Industry Association belongs to all. I will exert my utmost to service my members. I am grateful and eagerly seeking advice from my predecessors and co-workers, believing that collective wisdom works better than one’s.

Francis Hong
Chairman
Taiwan Medical and Biotech Industry Association